Harvard Bioscience, Inc. (HBIO) |
| 4.82 0.165 (3.54%) 04-14 15:48 |
| Open: | 4.99 |
| High: | 4.99 |
| Low: | 4.62 |
| Volume: | 61,320 |
| Market Cap: | 22(M) |
| PE Ratio: | -0.38 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 5.83 |
| Resistance 1: | 5.13 |
| Pivot price: | 5.03 |
| Support 1: | 4.00 |
| Support 2: | 3.33 |
| 52w High: | 9.5 |
| 52w Low: | 2.8 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
| EPS | -1.280 |
| Book Value | 3.070 |
| PEG Ratio | 0.00 |
| Gross Profit | 11.166 |
| Profit Margin (%) | -65.51 |
| Operating Margin (%) | 14.01 |
| Return on Assets (ttm) | 0.9 |
| Return on Equity (ttm) | -147.1 |
Tue, 14 Apr 2026
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Fri, 10 Apr 2026
HBIO | Harvard Bioscience Inc Insider Trading - Quiver Quantitative
Wed, 01 Apr 2026
Harvard Bioscience (NASDAQ: HBIO) CFO awarded 30,000 RSUs in equity grant - Stock Titan
Wed, 01 Apr 2026
Harvard Bioscience (HBIO) CFO adds 5,000 shares at $5.00 - Stock Titan
Mon, 16 Mar 2026
Benchmark raises Harvard Bioscience stock price target to $6 on reverse split - Investing.com
Thu, 12 Mar 2026
Harvard Bioscience (HBIO) Reports Q4 Loss of $0.06/Share, Revenue Falls 3.3% to $23.7M - AlphaStreet
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |